Stock Research: Sanofi India

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Sanofi India

BSE:500674 INE058A01010
14
  • Value
    67
  • Growth
    7
  • Safety
    Safety
    41
  • Combined
    16
  • Sentiment
    26
  • 360° View
    360° View
    14
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Sanofi India Limited manufactures and trades drugs and pharmaceuticals. The company focuses on therapeutic areas including diabetes (Lantus, Toustar), epilepsy (Frisium), cardiology (Cardace), allergy (Allegra, Avil), and pain care (Combiflam). It operates mainly in India, with a manufacturing facility in Goa and around 12 contract manufacturing organizations. In the last fiscal year, the company had a market cap of $1577 million, profits of $119 million, revenue of $235 million, and 991 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 14 (better than 14% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sanofi India are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Sanofi India. The only rank that is above average is the consolidated Safety Rank at 67, which means that the company has a financing structure that is safer than those of 67% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 41, which means that the share price of Sanofi India is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 7, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 26, which means that professional investors are more pessimistic about the stock than for 74% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
41 35 43 55
Growth
7 11 31 7
Safety
Safety
67 83 75 97
Sentiment
26 83 45 94
360° View
360° View
14 59 43 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
100 97 87 97
Opinions Change
10 50 50 50
Pro Holdings
n/a 50 25 92
Market Pulse
13 84 29 27
Sentiment
26 83 45 94
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
41 35 43 55
Growth
7 11 31 7
Safety Safety
67 83 75 97
Combined
16 23 47 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
58 42 50 50
Price vs. Earnings (P/E)
42 36 29 39
Price vs. Book (P/B)
10 10 14 43
Dividend Yield
74 67 76 82
Value
41 35 43 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
25 23 32 8
Profit Growth
14 12 59 32
Capital Growth
6 19 17 9
Stock Returns
23 47 83 25
Growth
7 11 31 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
80 84 82 92
Refinancing
20 32 32 48
Liquidity
89 90 88 92
Safety Safety
67 83 75 97

Similar Stocks

Discover high‑ranked alternatives to Sanofi India and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.